<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: oa--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11953857</article-id><article-id pub-id-type="pmc">2364174</article-id><article-id pub-id-type="pii">6600219</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6600219</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular and Cellular Pathology</subject></subj-group></article-categories><title-group><article-title>Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Huang</surname><given-names>G C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hobbs</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Walton</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Epstein</surname><given-names>R J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine, King's College School of Medicine, Bessemer Rd, London, SW3, UK</aff><aff id="aff2"><label>2</label>CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Cotswold Rd, Sutton SM2 5NG, Surrey, UK</aff><aff id="aff3"><label>3</label>Department of Metabolic Medicine, Imperial College School of Medicine, Du Cane Rd, London W12 0NN, UK</aff><aff id="aff4"><label>4</label>Division of Medical Sciences, National Cancer Centre, Hospital Drive, Singapore 169610</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:daarje@nccs.com.sg">daarje@nccs.com.sg</email></corresp></author-notes><pub-date pub-type="ppub"><day>08</day><month>04</month><year>2002</year></pub-date><volume>86</volume><issue>7</issue><fpage>1104</fpage><lpage>1109</lpage><history><date date-type="received"><day>03</day><month>01</month><year>2002</year></date><date date-type="accepted"><day>24</day><month>01</month><year>2002</year></date></history><copyright-statement>Copyright 2002, Cancer Research UK</copyright-statement><copyright-year>2002</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>We previously reported that the ErbB2 oncoprotein prolongs and amplifies growth factor signalling by impairing ligand-dependent downregulation of hetero-oligomerised epidermal growth factor receptors. Here we show that treatment of A431 cells with different epidermal growth factor receptor ligands can cause growth inhibition to an extent paralleling ErbB2 tyrosine phosphorylation. To determine whether such growth inhibition signifies an interaction between the cell cycle machinery and ErbB2-dependent alterations of cell signalling kinetics, we used MCF7 breast cancer cells (which express wild-type p53) to create transient and stable ErbB2 transfectants (MCF7-B2). Compared with parental cells, MCF7-B2 cells are characterised by upregulation of p53, p21<sup><italic>WAF</italic></sup> and Myc, downregulation of Bcl2, and apoptosis. In contrast, MCF7-B2 cells co-transfected with dominant negative p53 (MCF7-B2/&#x00394;p53) exhibit reduced apoptosis and enhanced growth relative to both parental MCF7-B2 and control cells. These data imply that wild-type p53 limits survival of ErbB2-overexpressing breast cancer cells, and suggest that signals of varying length and/or intensity may evoke different cell outcomes depending upon the integrity of cell cycle control genes. We submit that acquisition of cell cycle control defects may play a permissive role in ErbB2 upregulation, and that the ErbB2 overexpression phenotype may in turn select for the survival of cells with p53 mutations or other tumour suppressor gene defects.</p><p><italic>British Journal of Cancer</italic> (2002) <bold>86</bold>, 1104&#x02013;1109. DOI: <ext-link ext-link-type="doi" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1038/sj/bjc/6600219">10.1038/sj/bjc/6600219</ext-link> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.bjcancer.com">www.bjcancer.com</ext-link></p><p>&#x000a9; 2002 <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.crc.org.uk">Cancer Research UK</ext-link></p></abstract><kwd-group><kwd>ErbB2</kwd><kwd>p53</kwd><kwd>apoptosis</kwd></kwd-group></article-meta></front><body><sec><title/><p>The molecular pathways controlling cell growth and death are deeply intertwined, with gene products as diverse as Myc (<xref ref-type="other" rid="bib17">Evan <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib25">Harrington <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib4">Barone and Courtneidge, 1995</xref>; <xref ref-type="other" rid="bib48">Packham <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib30">Kauffmann-Zeh <italic>et al</italic>, 1997</xref>), Raf (<xref ref-type="other" rid="bib41">Morrison <italic>et al</italic>, 1989</xref>; <xref ref-type="other" rid="bib52">Pumiglia and Decker, 1997</xref>; <xref ref-type="other" rid="bib64">Woods <italic>et al</italic>, 1997</xref>) and MAP kinase (<xref ref-type="other" rid="bib59">Traverse <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib6">Ben-Levy <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib38">Marshall, 1995</xref>; <xref ref-type="other" rid="bib39">Marte <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib32">Kimura <italic>et al</italic>, 1999</xref>) being firmly implicated in both outcomes. By the same token, well-characterised mitogens such as the epidermal growth factor receptor (EGFR) and the ErbB2 (HER2/<italic>neu</italic>) oncoprotein have been causally linked to cell growth inhibition and apoptosis (<xref ref-type="other" rid="bib21">Gill and Lazar, 1981</xref>; <xref ref-type="other" rid="bib31">Kawamoto <italic>et al</italic>, 1984</xref>; <xref ref-type="other" rid="bib19">Filmus <italic>et al</italic>, 1985</xref>; <xref ref-type="other" rid="bib50">Polet, 1990</xref>; <xref ref-type="other" rid="bib57">Tagliabue <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib1">Armstrong <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib26">Harris <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib33">Kita <italic>et al</italic>, 1996</xref>). Since these molecules are often overexpressed in human breast tumours (<xref ref-type="other" rid="bib53">Sainsbury <italic>et al</italic>, 1985</xref>; <xref ref-type="other" rid="bib54">Slamon <italic>et al</italic>, 1989</xref>) &#x02013; subtypes of which exhibit prominent apoptosis (<xref ref-type="other" rid="bib8">Bodis <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib37">Liu <italic>et al</italic>, 1992</xref>) &#x02013; a better understanding of their pathogenetic significance could be relevant to anticancer drug development.</p><p>We previously reported that growth arrest of 3T3 cells is associated with catalytic activation of ErbB2 (<xref ref-type="other" rid="bib15">Epstein <italic>et al</italic>, 1990</xref>), and more recently demonstrated that ErbB2 lengthens and intensifies mitogenic signalling by impairing ligand-dependent EGFR downregulation (<xref ref-type="other" rid="bib28">Huang <italic>et al</italic>, 1999</xref>). In addition, we have shown that the functionally distinct EGFR ligands, EGF and transforming growth factor-alpha (TGF&#x003b1;), exert differing effects on EGFR downregulation and hence on the duration of ErbB2 co-activation: high concentrations of EGF initially cause prolonged EGFR activation associated with ErbB2 heterodimerisation, followed by eventual EGFR downregulation and signal cessation; whereas TGF&#x003b1; fails to downregulate EGFR, leading to sustained signalling (<xref ref-type="other" rid="bib23">Gulliford <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib45">Ouyang <italic>et al</italic>, 1999a</xref>). The possibility is thus raised that ErbB2 could mimic the tumorigenic effects of TGF&#x003b1; in cancer cells by its similar ability to prolong EGFR signalling.</p><p>The above-mentioned differential induction of growth stimulation or inhibition by EGFR (<xref ref-type="other" rid="bib19">Filmus <italic>et al</italic>, 1985</xref>; <xref ref-type="other" rid="bib50">Polet, 1990</xref>; <xref ref-type="other" rid="bib1">Armstrong <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib22">Gulli <italic>et al</italic>, 1996</xref>) and ErbB2 (<xref ref-type="other" rid="bib57">Tagliabue <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib26">Harris <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib33">Kita <italic>et al</italic>, 1996</xref>) strongly suggests an interaction between downstream signal duration (e.g. of MAP kinase) and cell cycle control proteins (<xref ref-type="other" rid="bib59">Traverse <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib38">Marshall, 1995</xref>). To address the possibility that ErbB2-dependent changes in signal duration may contribute to such differences in cell fate, it is necessary to create cell systems in which the effects of ErbB2 expression can be correlated with the function or dysfunction of a given cell cycle regulatory molecule. Here we show that the effects of ErbB2 on cell signalling kinetics are selectively associated with induction of apoptosis in oestrogen-responsive MCF7 human breast cancer cells &#x02013; which, like most hormone-sensitive cancers (<xref ref-type="other" rid="bib9">Caleffi <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib14">Elledge <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib7">Berns <italic>et al</italic>, 2000</xref>), express wild-type p53 (<xref ref-type="other" rid="bib10">Casey <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib3">Balcer-Kubiczek <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib20">Furuwatari <italic>et al</italic>, 1998</xref>) but normally do not overexpress ErbB2 (<xref ref-type="other" rid="bib65">Wright <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib18">Ferrero-Pous <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib49">Pinto <italic>et al</italic>, 2001</xref>). Dominant negative knockout of p53 converts growth inhibition to growth enhancement in these ErbB2-transfected cells, suggesting that a p53 mutational pathway could favour selection for ErbB2 gene amplification during tumour progression.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Cell lines, reagents, antibodies, and immunoblotting</title><p>MCF7 and A431 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Synthetic human EGF and TGF&#x003b1; were purchased from Sigma. Activation-state-specific EGFR antibodies, and antibodies to p53, Myc, Bcl2 and p21<sup><italic>WAF</italic></sup>, were purchased from Cambridge BioScience (Cambridge, UK). Polyclonal antibodies to Tyr<sup>1248</sup>- and Tyr<sup>1222</sup>-phosphorylated ErbB2 were developed and validated for receptor-specificity as described previously (<xref ref-type="other" rid="bib16">Epstein <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib44">Ouyang <italic>et al</italic>, 1998</xref>). For immunoblotting studies, cells were lysed as previously described (<xref ref-type="other" rid="bib23">Gulliford <italic>et al</italic>, 1997</xref>): protein lysates were immediately boiled for 5&#x02009;min in sample buffer (6.7&#x00025; sodium dodecyl sulfate, 30&#x00025; glycerol, 62.5&#x02009;m<sc>M</sc> Tris base pH&#x02009;6.8, 0.01&#x00025; bromophenol blue) then loaded onto a 7.5&#x00025; SDS-polyacrylamide gel. Samples were electrophoresed and transblotted onto nitrocellulose as described (<xref ref-type="other" rid="bib58">Towbin <italic>et al</italic>, 1979</xref>).</p></sec><sec><title>Growth curves and apoptosis assays</title><p>Cell growth was measured using a multiwell colorimetric assay based on sulphorhodamine B (SRB) spectrophotometric detection. Confirmation and quantification of morphologic apoptosis was performed using a Tdt-mediated dUTP nick-end labelling (TUNEL) kit to directly detect DNA fragmentation <italic>in situ</italic>. Briefly, cells were plated and grown on glass slides, treated with ligand for the required period, then fixed in 4&#x00025; paraformaldehyde for 30&#x02009;min at room temperature. The slides were washed with PBS three times, after which the cells were permeabilised with 0.1&#x00025; Triton-X-100 in 0.1&#x00025; sodium citrate for 10&#x02009;min. After washing, the cells were covered in 50&#x02009;&#x003bc;l of equilibration solution for 10&#x02009;min, then covered with 50&#x02009;&#x003bc;l of labelling solution (Biovation) and incubated at 37&#x000b0;C for 1&#x02009;h while light-protected. The slides were then washed, covered in 10&#x02009;&#x003bc;l counterstain for 10&#x02009;min, and analysed using fluorescence microscopy.</p></sec><sec><title>Cell transfection</title><p>For calcium phosphate transfection, cells were seeded in 90&#x02009;mm diameter cell culture dishes at 5&#x000d7;10<sup>5</sup>&#x02009;cells ml<sup>&#x02212;1</sup> 24&#x02009;h before the transfection. One plate was required for each transfection experiment; the monolayer normally grew to 80&#x00025; confluence by the following day, and the medium was changed 3&#x02009;h before the transfection. Two sterile microfuge tubes were labelled for each transfection experiment: to one tube was added 500&#x02009;&#x003bc;l of 2&#x000d7;BBS (pH&#x02009;6.95) and to the other tube was added 125&#x02009;&#x003bc;l of 1&#x02009;<sc>M</sc> CaCl<sub>2</sub>, 10&#x02013;20&#x02009;&#x003bc;g of recombinant plasmid DNA which contained the relevant cDNA; distilled H<sub>2</sub>O was added to give a final volume of 500&#x02009;&#x003bc;l. This was added to equal the volume of 2&#x000d7;concentrated BBS using a sterile Pasteur pipette. At the same time, filtered air was passed through the 2&#x000d7;BBS buffer (pH&#x02009;6.95) with a second Pasteur pipette, and the DNA mixture was then incubated at room temperature for 20&#x02009;min to allow precipitation. The DNA/CaPO<sub>4</sub> precipitate was mixed by inverting the tube, and was added directly to a 10&#x02009;ml cultured cell dish dropwise with gentle shaking, and the cell culture incubated at 37&#x000b0;C with 3&#x00025; CO<sub>2</sub> overnight followed by washing with PBS and re-culturing in fresh medium at 37&#x000b0;C with 5&#x00025; CO<sub>2</sub>.</p></sec><sec><title>Constructs and selection procedures</title><p>The well-characterised temperature-sensitive dominant negative p53 construct (<xref ref-type="other" rid="bib34">Kuerbitz <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib55">Slichenmeyer <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib68">Zhang <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib63">Vasey <italic>et al</italic>, 1996</xref>) was kindly provided by Dr B Vogelstein (<xref ref-type="other" rid="bib2">Baker <italic>et al</italic>, 1990</xref>). For selection, transfected cells were plated at 5&#x000d7;10<sup>4</sup>&#x02009;cells/9&#x02009;cm tissue culture dish with relevant reagents: dominant negative p53 was selected with neomycin. The wild-type ErbB2 construct, which is under the control of the Moloney murine leukaemia virus LTR and contains the <italic>Ecogpt</italic> selectable marker from <italic>E. coli</italic> (<xref ref-type="other" rid="bib12">Di Fiore <italic>et al</italic>, 1987</xref>), was selected with HAT (hypoxanthine, aminopterin and thymidine) as described by <xref ref-type="other" rid="bib42">Mulligan and Berg (1981)</xref>. For double transfection a pool of six p53 dominant negative clones (&#x00394;p53) or p53 empty vector clones were transfected with either ErbB2 or ErbB2 empty vector, and selected with HAT medium for at least 6 weeks. Resistant colonies were cloned and a pool of six clones was cultured with HAT medium to amplify the cell number. For analysis, the cells were cultured in normal medium for at least 2 weeks before the experiments were performed. For morphologic analysis, cells were grown in plastic 8-chamber containers (LabTek; Gibco) and the monolayers photographed using a Zeiss microscope. Growth experiments were carried out in 96-well plates using quantification of Hoechst dye immunofluorescence in six matched samples following 3 days growth to assess cumulative DNA content.</p></sec></sec><sec><title>RESULTS</title><p>Consistent with earlier reports (<xref ref-type="other" rid="bib21">Gill and Lazar, 1981</xref>; <xref ref-type="other" rid="bib50">Polet, 1990</xref>), ligand stimulation experiments confirm EGF-dependent growth inhibition of sparsely-plated A431 cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref><fig id="fig1"><label>Figure 1</label><caption><p>Relative effects of EGF and TGF&#x003b1; on cell growth, growth inhibition, and ErbB2 tyrosine phosphorylation of A431&#x02009;cells. (<bold>A</bold>) Effects of differential ligand treatment on cell growth, relative to growth of untreated controls (upper figure) and to ligand-dependent ErbB2 tyrosine phosphorylation (lower figure). In the upper figure, cells were plated at 1.5&#x000d7;10<sup>4&#x02009;</sup>ml<sup>&#x02212;1</sup> seeding density and stimulated for 6 days with the respective ligand (EGF, solid columns; TGF&#x003b1;, open columns) prior to counting using a sulphorhodamine-based assay as described. Nanomolar ligand concentrations are represented on the abscissa. The results are expressed as a percentage change relative to control cell growth; error bars are based on six measurements. The lower figure shows the corresponding short-term effects of EGF and TGF&#x003b1; on ErbB2 Y<sup>1222</sup> phosphorylation: cells were treated for 5&#x02009;min with EGF or TGF&#x003b1; at the indicated nanomolar concentration prior to lysis, electrophoresis and immunoblotting using aPY<sup>1222</sup>. The bands were visualised using ECL. (<bold>B</bold>) Visualisation of cell death by light microscopy and TUNEL assay (see Materials and Methods) associated with ligand treatment. Twenty-four hours following attachment, cells were treated with the respective ligands (2&#x02009;n<sc>M</sc>) in serum-free medium. Typical low-power views of triplicate plates are shown after 48&#x02009;h treatment using light microscopy (above) and fluorescence microscopy (below).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="86-6600219f1"/></fig>, upper panel). The extent of growth inhibition correlates with the intensity of equimolar ligand-dependent ErbB2 tyrosine phosphorylation as detected by site-specific phosphoantibodies (<xref ref-type="other" rid="bib44">Ouyang <italic>et al</italic>, 1998</xref>) which confirm greater ErbB2 tyrosine phosphorylation following EGF stimulation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, lower panel). As reported previously, this initial difference in ligand-dependent signal intensity is maintained and further exaggerated over the subsequent 12&#x02009;h (<xref ref-type="other" rid="bib45">Ouyang <italic>et al</italic>, 1999a</xref>). Correlation of light microscopy with TUNEL assay indicates that the growth-inhibitory effects of EGF in this context are associated with increased apoptosis (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><p>The foregoing data do not distinguish whether the observed growth inhibition is induced by ligand-dependent ErbB2 co-activation <italic>per se</italic> or, alternatively, by the downstream consequences of growth factor signal prolongation induced by ligand-dependent ErbB2 heterodimerisation. However, since our previous work documented a marked prolongation of EGFR signalling by ErbB2 expression (<xref ref-type="other" rid="bib28">Huang <italic>et al</italic>, 1999</xref>), we elected to test the latter hypothesis by creating ErbB2 transfectants in cell lines differing solely in terms of cell cycle control functionality. To this end, MCF7 human breast cancer cells known to express both copies of the wild-type p53 gene (<xref ref-type="other" rid="bib10">Casey <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib3">Balcer-Kubiczek <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib20">Furuwatari <italic>et al</italic>, 1998</xref>) were transiently transfected with ErbB2. As shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref><fig id="fig2"><label>Figure 2</label><caption><p>Effects of transient ErbB2 transfection on parental MCF7 cells. (<bold>A</bold>) Effects of ErbB2 transfection on protein expression. Control (lane 1; vector-only) and ErbB2-transfected cells (lane 2) were lysed and assessed by immunoblotting. EGFR&#x0002a;, kinase-active epidermal growth factor receptor; 1248, ErbB2 tyrosine-phosphorylated at position 1248, detected by the activation-specific aPY<sup>1248</sup> antibody (<xref ref-type="other" rid="bib44">Ouyang <italic>et al</italic>, 1998</xref>). (<bold>B</bold>) Effects of ErbB2 expression on morphology and apoptosis of MCF7 human breast cancer cells assessed using light microscopy. ErbB2 transfectants (at right) were generated using a standard calcium phosphate transfection procedure followed by neomycin selection. Mock transfectants containing empty plasmids are shown at left.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="86-6600219f2"/></fig>, ErbB2 expression in these cells induces increased immunoreactivity of both activated ErbB2 and EGFR, consistent with previous studies (<xref ref-type="other" rid="bib29">Huang <italic>et al</italic>, 1998</xref>, <xref ref-type="other" rid="bib28">1999</xref>), while also inducing increased expression of p53, p21<sup><italic>WAF</italic></sup> and Myc. Of note, ErbB2 expression is associated with reduced <italic>Bcl</italic>2 expression &#x02013; an effect reported previously following primary overexpression of p53 (<xref ref-type="other" rid="bib24">Haldar <italic>et al</italic>, 1994</xref>). These effects on protein expression are accompanied by morphologic changes (membrane blebbing, chromatin condensation) typical of apoptosis in ErbB2-transfected, but not vector control, cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). These ErbB2-dependent changes in protein expression and morphology directly implicate ErbB2 in the activation of an apoptotic pathway.</p><p>To clarify whether the apoptosis-triggering effect of ErbB2 might be at least partly related to its effects on signalling kinetics (i.e. as opposed to an exclusive cell-killing effect of ErbB2 kinase activity), stable MCF7 cell transfectants were created using either the wild-type ErbB2 gene, the dominant-negative p53 mutant gene, or both. As in the ErbB2 transient transfectants, stable overexpression of ErbB2 selectively induces endogenous (wild-type) p53 protein overexpression (<xref ref-type="fig" rid="fig3">Figure 3A</xref><fig id="fig3"><label>Figure 3</label><caption><p>Effects of stable ErbB2 overexpression and/or p53 knockout on MCF7 cell protein function as measured by expression of p53 and p21<sup><italic>WAF</italic></sup> in ErbB2 and/or mutant p53 transfectants and controls. (<bold>A</bold>) p53 immunoblot. Control, parental MCF7 cells; B2 vector, MCF7 transfected with vector alone; B2, MCF7 transfected with vector containing ErbB2 cDNA; p53&#x00394;, MCF7 transfected with dominant negative mutant p53; p53&#x00394; vector, MCF7 transfected with dominant negative p53 and also with empty vector used for ErbB2 studies; p53&#x00394;/B2, MCF7 cells transfected with dominant negative mutant p53 and with ErbB2. <italic>B</italic>, p21<sup><italic>WAF</italic></sup> immunoblot. As indicated by the legend below, cells from even-numbered lanes received radiotherapy (RT) with 0.1&#x02009;Gy X-irradiation prior to lysis. Odd-numbered lanes represent the sample order described for the upper panel.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="86-6600219f3"/></fig>, upper panel, left three lanes); as expected, dominant-negative mutant p53 (&#x00394;p53) cells grossly overexpress immunoreactive p53 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, upper panel, right three lanes). Irradiated control and ErbB2-transfected MCF7 cells exhibit a normal increase in p21<sup><italic>WAF</italic></sup> expression following X-irradiation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, lower panel, left 6 lanes). In contrast, MCF7-&#x00394;p53 cells sustain no immunodetectable rise in p21<sup><italic>WAF</italic></sup> levels (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, lower panel, right 6 lanes), thus validating the functionality of the dominant-negative p53 construct used in these experiments. Of note, p21<sup><italic>WAF</italic></sup> was not detectably overexpressed in stable ErbB2-overexpressing cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) unlike in transient transfectants (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), raising the possibility that prolonged ErbB2 overexpression induces clonal selection.</p><p>The four transfectant cell lines of interest &#x02013; parental MCF7, MCF7-B2, MCF7-&#x00394;p53, and MCF7-B2/&#x00394;p53 &#x02013; were then compared with respect to morphology and growth. Unlike parental MCF7 cells which adopt a spread-out cell appearance suggesting density-dependent growth inhibition (<xref ref-type="fig" rid="fig4">Figure 4A</xref><fig id="fig4"><label>Figure 4</label><caption><p>Effects of ErbB2 overexpression and/or p53 knockout on MCF7 cell morphology and growth. (<bold>A</bold>) Morphology of MCF7 cell variants characterised by light microscopy. Top left, parental MCF7 cells; top right, MCF7 transfected with mutant p53; lower left, MCF7 transfected with wild-type ErbB2; lower right, MCF7 co-transfected with both mutant p53 and wild-type ErbB2. (<bold>B</bold>) Cell growth of MCF7 variants following 3 days growth. Error bars represent standard errors of the mean based on six identical samples for each cell line. Abbreviations are as above.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="86-6600219f4"/></fig>, upper left), all of the other transfectants exhibit a crowded morphology. MCF7-B2 cells also exhibit striking apoptosis (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, lower left), however, a feature which is absent from both the MCF7-&#x00394;p53 and MCF7-B2/&#x00394;p53 cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, right upper and lower panels, respectively). Cell growth as measured by Coulter counting was increased in MCF7-&#x00394;p53 cells and reduced in MCF7-B2 cells relative to parental cell growth: MCF7-B2/&#x00394;p53 cells exhibit more rapid growth than parental cells, though slower than MCF7-&#x00394;p53 cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Given the foregoing results, these data indicate that the observed ErbB2-dependent effects on cell fate vary with the functional status of p53, suggesting in turn that p53 may act as a sensor for ErbB2-induced changes in cell signalling kinetics.</p></sec><sec><title>DISCUSSION</title><p>We previously showed that ErbB2 expression causes constitutive EGF signalling by retarding downregulation of hetero-oligomerised EGFR (<xref ref-type="other" rid="bib28">Huang <italic>et al</italic>, 1999</xref>). This effect most likely relates to the absence of motifs in the ErbB2 C-terminal tail for receptor internalisation and degradation (<xref ref-type="other" rid="bib56">Sorkin <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib5">Baulida <italic>et al</italic>, 1996</xref>). Since human tumours exclusively overexpress the wild-type ErbB2 rather than the transforming point mutant (<xref ref-type="other" rid="bib35">Lemoine <italic>et al</italic>, 1990</xref>), a reasonable hypothesis is that tumour cells acquire a growth advantage from wild-type ErbB2 overexpression, but that this phenotype does not represent the primary transforming event &#x02013; implying the co-existence, that is, of at least one other molecular defect within the tumour cells. This hypothesis is consistent with numerous reports linking tumour cell ErbB2 overexpression and p53 dysfunction (<xref ref-type="other" rid="bib27">Horak <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib40">Mehta <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib36">Li <italic>et al</italic>, 1997</xref>) and identifying poor-prognosis clinical subgroups based on concurrence of these phenotypes (<xref ref-type="other" rid="bib60">Tsuda <italic>et al</italic>, 1998</xref>). Moreover, our recent documentation of differential survival outcomes in ErbB2-overexpressing breast cancers associated with different phosphorylation patterns (<xref ref-type="other" rid="bib46">Ouyang <italic>et al</italic>, 1999b</xref>, <xref ref-type="other" rid="bib47">2001</xref>) supports the notion of multiple signalling pathways governing tumour growth phenotypes.</p><p>Given that the p53 checkpoint prevents cell-cycle progression when activated (<xref ref-type="other" rid="bib10">Casey <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib67">Yin <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib66">Wyllie <italic>et al</italic>, 1995</xref>) and that the duration of growth factor signalling influences whether cells proliferate or arrest (<xref ref-type="other" rid="bib59">Traverse <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib38">Marshall, 1995</xref>), the present study suggests a model of cell signal sensing which is differentially perturbed by ErbB2 depending upon the functional p53 status. Other studies have concluded that the main <italic>in vitro</italic> and <italic>in vivo</italic> consequences of p53 mutation on cell growth relate to enhanced proliferation rather than to reduced apoptosis (<xref ref-type="other" rid="bib43">Nikiforov <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib61">Tyner <italic>et al</italic>, 1999</xref>). Our data suggest a more complex interpretation of p53 function as a co-variable within the cell growth machinery; this is consistent with the surprising finding in human tumours that p53 mutation is often associated with increased, rather than decreased, apoptotic indices (<xref ref-type="other" rid="bib62">van Slooten <italic>et al</italic>, 1999</xref>). In the context of tumour progression, it is important to note that apoptosis could represent a mechanism of clonal selection for more aggressive cell lineages, rather than simply indicating a benign tumour-suppressive function.</p><p>Reductions in mitogenic signal intensity may normally cause cells to arrest and/or differentiate, whereas signal prolongation may trigger differentiation or death (<xref ref-type="other" rid="bib59">Traverse <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib13">Dolmetsch <italic>et al</italic>, 1997</xref>). According to this paradigm, apoptosis may be inducible by forced cell cycle progression in the presence of activated checkpoints (<xref ref-type="other" rid="bib50">Polet, 1990</xref>). Abrogation of p53 function by mutation could thus prevent cells from sensing an abnormally prolonged signal, leading to loss of growth arrest, reduced apoptosis and differentiation, and consequent outgrowth of less differentiated cells. In contrast, ErbB2-dependent impairment of EGFR downregulation both prolongs and intensifies growth factor signalling (<xref ref-type="other" rid="bib28">Huang <italic>et al</italic>, 1999</xref>), an outcome associated with the increased apoptosis reported here. Such an effect of ErbB2 might be expected to be short-lived, given that selection for apoptotic resistance should be rapid (<xref ref-type="other" rid="bib3">Balcer-Kubiczek <italic>et al</italic>, 1995</xref>). Acquisition of a p53 defect in this context would cause mutant cells to &#x02018;perceive&#x02019; mitogenic signals as short despite ErbB2-dependent signal prolongation &#x02013; leading to apoptotic resistance, dedifferentiation and clonal outgrowth.</p><p>Human tumours could thus evolve from an interplay between progressive ErbB2 overexpression and acquisition of cell-cycle control defects including, though not necessarily limited to, p53 mutations. We therefore submit that human tissues with cell-cycle control defects (<xref ref-type="other" rid="bib11">De Cremoux <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib51">Prevo <italic>et al</italic>, 1999</xref>) may gain a growth advantage by prolonging and intensifying ambient growth factor signals via ErbB2 upregulation, and that tumour cells overexpressing ErbB2 may in turn clonally select for cell-cycle checkpoint loss (<xref ref-type="other" rid="bib36">Li <italic>et al</italic>, 1997</xref>).</p></sec></body><back><ack><p>We thank Dr B Vogelstein for kind provision of the p53 dominant negative mutant, and Professor SR Bloom for support. This work was funded by NIH R01 grant 61953 and by Cancer Research UK.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>DK</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name><name><surname>Ottaviano</surname><given-names>YL</given-names></name><etal/></person-group><article-title>Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>5280</fpage><lpage>5283</lpage><!--PubMed citation query: 'Cancer Res||54|5280||bib1|'--><pub-id pub-id-type="pmid">7923154</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>SJ</given-names></name><name><surname>Markowitz</surname><given-names>S</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Willson</surname><given-names>JK</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Suppression of human colorectal carcinoma cell growth by wild-type p53</article-title><source>Science</source><year>1990</year><volume>249</volume><fpage>912</fpage><lpage>915</lpage><!--PubMed citation query: 'Science||249|912||bib2|'--><pub-id pub-id-type="pmid">2144057</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balcer-Kubiczek</surname><given-names>EK</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Harrison</surname><given-names>GH</given-names></name><name><surname>Abraham</surname><given-names>JM</given-names></name><name><surname>Meltzer</surname><given-names>SJ</given-names></name></person-group><article-title>p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons</article-title><source>Radiat Res</source><year>1995</year><volume>142</volume><fpage>256</fpage><lpage>262</lpage><!--PubMed citation query: 'Radiat Res||142|256||bib3|'--><pub-id pub-id-type="pmid">7761574</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barone</surname><given-names>MV</given-names></name><name><surname>Courtneidge</surname><given-names>SA</given-names></name></person-group><article-title>Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>509</fpage><lpage>512</lpage><!--PubMed citation query: 'Nature||378|509||bib4|'--><pub-id pub-id-type="pmid">7477410</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baulida</surname><given-names>J</given-names></name><name><surname>Kraus</surname><given-names>MH</given-names></name><name><surname>Alimandi</surname><given-names>M</given-names></name><name><surname>Di Fiore</surname><given-names>PP</given-names></name><name><surname>Carpenter</surname><given-names>G</given-names></name></person-group><article-title>All erbB receptors other than the epidermal growth factor receptor are endocytosis impaired</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>5251</fpage><lpage>5257</lpage><!--PubMed citation query: 'J Biol Chem||271|5251||bib5|'--><pub-id pub-id-type="pmid">8617810</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Levy</surname><given-names>R</given-names></name><name><surname>Paterson</surname><given-names>HF</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><article-title>A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway</article-title><source>EMBO J</source><year>1994</year><volume>13</volume><fpage>3302</fpage><lpage>3311</lpage><!--PubMed citation query: 'EMBO J||13|3302||bib6|'--><pub-id pub-id-type="pmid">7913890</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berns</surname><given-names>EM</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Vossen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>2155</fpage><lpage>2162</lpage><!--PubMed citation query: 'Cancer Res||60|2155||bib7|'--><pub-id pub-id-type="pmid">10786679</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bodis</surname><given-names>S</given-names></name><name><surname>Siziopikou</surname><given-names>KP</given-names></name><name><surname>Schnitt</surname><given-names>SJ</given-names></name><name><surname>Harris</surname><given-names>JR</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name></person-group><article-title>Extensive apoptosis in ductal carcinoma in situ of the breast</article-title><source>Cancer</source><year>1996</year><volume>77</volume><fpage>1831</fpage><lpage>1835</lpage><!--PubMed citation query: 'Cancer||77|1831||bib8|'--><pub-id pub-id-type="pmid">8646681</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caleffi</surname><given-names>M</given-names></name><name><surname>Teague</surname><given-names>MW</given-names></name><name><surname>Jensen</surname><given-names>RA</given-names></name><name><surname>Vnencak-Jones</surname><given-names>CL</given-names></name><name><surname>Dupont</surname><given-names>WD</given-names></name><name><surname>Parl</surname><given-names>FF</given-names></name></person-group><article-title>p53 gene mutations and steroid receptor status in breast cancer: clinicopathologic correlations and prognostic assessment</article-title><source>Cancer</source><year>1994</year><volume>73</volume><fpage>2147</fpage><lpage>2156</lpage><!--PubMed citation query: 'Cancer||73|2147||bib9|'--><pub-id pub-id-type="pmid">8156519</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>G</given-names></name><name><surname>Lo-Hsueh</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>ME</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Stanbridge</surname><given-names>EJ</given-names></name></person-group><article-title>Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene</article-title><source>Oncogene</source><year>1991</year><volume>6</volume><fpage>1791</fpage><lpage>1797</lpage><!--PubMed citation query: 'Oncogene||6|1791||bib10|'--><pub-id pub-id-type="pmid">1923504</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Cremoux</surname><given-names>P</given-names></name><name><surname>Salomon</surname><given-names>AV</given-names></name><name><surname>Liva</surname><given-names>S</given-names></name><etal/></person-group><article-title>p53 mutation as a genetic trait of typical medullary breast carcinoma</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>641</fpage><lpage>643</lpage><!--PubMed citation query: 'J Natl Cancer Inst||91|641||bib11|'--><pub-id pub-id-type="pmid">10203285</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Fiore</surname><given-names>PP</given-names></name><name><surname>Pierce</surname><given-names>JH</given-names></name><name><surname>Kraus</surname><given-names>KH</given-names></name><name><surname>Segatto</surname><given-names>O</given-names></name><name><surname>King</surname><given-names>CR</given-names></name><name><surname>Aaronson</surname><given-names>SA</given-names></name></person-group><article-title><italic>erb</italic>B-2 is a potent oncogene when overexpressed in NIH/3T3 cells</article-title><source>Science</source><year>1987</year><volume>237</volume><fpage>178</fpage><lpage>181</lpage><!--PubMed citation query: 'Science||237|178||bib12|'--><pub-id pub-id-type="pmid">2885917</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dolmetsch</surname><given-names>RE</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name><name><surname>Healy</surname><given-names>JI</given-names></name></person-group><article-title>Differential activation of transcription factors induced by calcium response amplitude and duration</article-title><source>Nature</source><year>1997</year><volume>386</volume><fpage>855</fpage><lpage>857</lpage><!--PubMed citation query: 'Nature||386|855||bib13|'--><pub-id pub-id-type="pmid">9126747</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elledge</surname><given-names>RM</given-names></name><name><surname>Lock-Lim</surname><given-names>S</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Hilsenbeck</surname><given-names>SG</given-names></name><name><surname>Cordner</surname><given-names>L</given-names></name></person-group><article-title>p53 mutation and tamoxifen resistance in breast cancer</article-title><source>Clin Cancer Res</source><year>1995</year><volume>1</volume><fpage>1203</fpage><lpage>1208</lpage><!--PubMed citation query: 'Clin Cancer Res||1|1203||bib14|'--><pub-id pub-id-type="pmid">9815913</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>RJ</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Stiles</surname><given-names>CD</given-names></name></person-group><article-title>Modulation of a 175-kDa c-neu receptor isoform in G8/DHFR cells by serum starvation</article-title><source>J Biol Chem</source><year>1990</year><volume>265</volume><fpage>10746</fpage><lpage>10751</lpage><!--PubMed citation query: 'J Biol Chem||265|10746||bib15|'--><pub-id pub-id-type="pmid">1972380</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>RJ</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Stiles</surname><given-names>CD</given-names></name></person-group><article-title>Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-<italic>erb</italic>B-2 receptor</article-title><source>Proc Natl Acad Sci USA</source><year>1992</year><volume>89</volume><fpage>10435</fpage><lpage>10439</lpage><!--PubMed citation query: 'Proc Natl Acad Sci USA||89|10435||bib16|'--></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evan</surname><given-names>GI</given-names></name><name><surname>Wyllie</surname><given-names>AH</given-names></name><name><surname>Gilbert</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Induction of apoptosis in fibroblasts by c-myc protein</article-title><source>Cell</source><year>1992</year><volume>69</volume><fpage>119</fpage><lpage>128</lpage><!--PubMed citation query: 'Cell||69|119||bib17|'--><pub-id pub-id-type="pmid">1555236</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrero-Pous</surname><given-names>M</given-names></name><name><surname>Hacene</surname><given-names>K</given-names></name><name><surname>Bouchet</surname><given-names>C</given-names></name><name><surname>Le Doussal</surname><given-names>V</given-names></name><name><surname>Tubiana-Hulin</surname><given-names>M</given-names></name><name><surname>Spyratos</surname><given-names>F</given-names></name></person-group><article-title>Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>4745</fpage><lpage>4754</lpage><!--PubMed citation query: 'Clin Cancer Res||6|4745||bib18|'--><pub-id pub-id-type="pmid">11156229</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filmus</surname><given-names>J</given-names></name><name><surname>Pollak</surname><given-names>MN</given-names></name><name><surname>Cailleau</surname><given-names>R</given-names></name><name><surname>Buick</surname><given-names>RN</given-names></name></person-group><article-title>MDA-468, a human breast cancer cell line with a high number of epidermal growth factor receptors, has an amplified EGF receptor gene and is growth inhibited by EGF</article-title><source>Biochem Biophys Res Comm</source><year>1985</year><volume>128</volume><fpage>898</fpage><lpage>905</lpage><!--PubMed citation query: 'Biochem Biophys Res Comm||128|898||bib19|'--></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furuwatari</surname><given-names>C</given-names></name><name><surname>Yagi</surname><given-names>A</given-names></name><name><surname>Yamagami</surname><given-names>O</given-names></name><etal/></person-group><article-title>A comprehensive system to explore p53 mutations</article-title><source>Am J Clin Pathol</source><year>1998</year><volume>110</volume><fpage>368</fpage><lpage>373</lpage><!--PubMed citation query: 'Am J Clin Pathol||110|368||bib20|'--><pub-id pub-id-type="pmid">9728612</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>GN</given-names></name><name><surname>Lazar</surname><given-names>CS</given-names></name></person-group><article-title>Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells</article-title><source>Nature</source><year>1981</year><volume>293</volume><fpage>305</fpage><lpage>307</lpage><!--PubMed citation query: 'Nature||293|305||bib21|'--><pub-id pub-id-type="pmid">6268987</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gulli</surname><given-names>LF</given-names></name><name><surname>Palmer</surname><given-names>KC</given-names></name><name><surname>Chen</surname><given-names>YQ</given-names></name><name><surname>Reddy</surname><given-names>KB</given-names></name></person-group><article-title>Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity</article-title><source>Cell Growth Differ</source><year>1996</year><volume>7</volume><fpage>173</fpage><lpage>178</lpage><!--PubMed citation query: 'Cell Growth Differ||7|173||bib22|'--><pub-id pub-id-type="pmid">8822200</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gulliford</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>GC</given-names></name><name><surname>Ouyang</surname><given-names>X</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name></person-group><article-title>Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2</article-title><source>Oncogene</source><year>1997</year><volume>15</volume><fpage>2219</fpage><lpage>2223</lpage><!--PubMed citation query: 'Oncogene||15|2219||bib23|'--><pub-id pub-id-type="pmid">9393980</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haldar</surname><given-names>S</given-names></name><name><surname>Negrini</surname><given-names>M</given-names></name><name><surname>Monne</surname><given-names>M</given-names></name><name><surname>Sabbioni</surname><given-names>S</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>Down-regulation of bcl-2 by p53 in breast cancer cells</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>2095</fpage><lpage>2097</lpage><!--PubMed citation query: 'Cancer Res||54|2095||bib24|'--><pub-id pub-id-type="pmid">8174112</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>EA</given-names></name><name><surname>Bennett</surname><given-names>MR</given-names></name><name><surname>Fanidi</surname><given-names>A</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><article-title>c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines</article-title><source>EMBO J</source><year>1994</year><volume>13</volume><fpage>3286</fpage><lpage>3295</lpage><!--PubMed citation query: 'EMBO J||13|3286||bib25|'--><pub-id pub-id-type="pmid">8045259</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>RA</given-names></name><name><surname>Hiles</surname><given-names>ID</given-names></name><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>O'Hare</surname><given-names>MJ</given-names></name></person-group><article-title>The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-<italic>neu</italic> and its abrogation by glucocorticoids</article-title><source>Br J Cancer</source><year>1995</year><volume>72</volume><fpage>386</fpage><lpage>392</lpage><!--PubMed citation query: 'Br J Cancer||72|386||bib26|'--><pub-id pub-id-type="pmid">7640223</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horak</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Bromley</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mutant p53, EGF receptor and c-<italic>erb</italic>B-2 expression in human breast cancer</article-title><source>Oncogene</source><year>1991</year><volume>6</volume><fpage>2277</fpage><lpage>2284</lpage><!--PubMed citation query: 'Oncogene||6|2277||bib27|'--><pub-id pub-id-type="pmid">1685017</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>GC</given-names></name><name><surname>Ouyang</surname><given-names>X</given-names></name><name><surname>Chantry</surname><given-names>A</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name></person-group><article-title>Overexpression of ErbB2 impairs downregulation of epidermal growth factor receptors via a post-transcriptional mechanism</article-title><source>J Cell Biochem</source><year>1999</year><volume>74</volume><fpage>23</fpage><lpage>30</lpage><!--PubMed citation query: 'J Cell Biochem||74|23||bib28|'--><pub-id pub-id-type="pmid">10381258</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>GC</given-names></name><name><surname>Ouyang</surname><given-names>X</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name></person-group><article-title>Proxy activation of ErbB2 by heterologous ligands suggests a heterotetrameric mechanism of receptor tyrosine kinase interaction</article-title><source>Biochem J</source><year>1998</year><volume>331</volume><fpage>113</fpage><lpage>119</lpage><!--PubMed citation query: 'Biochem J||331|113||bib29|'--><pub-id pub-id-type="pmid">9512468</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kauffmann-Zeh</surname><given-names>A</given-names></name><name><surname>Rodriguez-Viciana</surname><given-names>P</given-names></name><name><surname>Ulrich</surname><given-names>E</given-names></name><etal/></person-group><article-title>Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB</article-title><source>Nature</source><year>1997</year><volume>385</volume><fpage>544</fpage><lpage>548</lpage><!--PubMed citation query: 'Nature||385|544||bib30|'--><pub-id pub-id-type="pmid">9020362</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>T</given-names></name><name><surname>Mendelsohn</surname><given-names>J</given-names></name><name><surname>Le</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>GH</given-names></name><name><surname>Lazar</surname><given-names>CS</given-names></name><name><surname>Gill</surname><given-names>GN</given-names></name></person-group><article-title>Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells</article-title><source>J Biol Chem</source><year>1984</year><volume>259</volume><fpage>7761</fpage><lpage>7766</lpage><!--PubMed citation query: 'J Biol Chem||259|7761||bib31|'--><pub-id pub-id-type="pmid">6330080</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Ohmichi</surname><given-names>M</given-names></name><name><surname>Kurachi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Role of mitogen-activated protein kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>5133</fpage><lpage>5142</lpage><!--PubMed citation query: 'Cancer Res||59|5133||bib32|'--><pub-id pub-id-type="pmid">10537288</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kita</surname><given-names>Y</given-names></name><name><surname>Tseng</surname><given-names>J</given-names></name><name><surname>Horan</surname><given-names>T</given-names></name><etal/></person-group><article-title>ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-HER2 monoclonal antibodies</article-title><source>Biochem Biophys Res Comm</source><year>1996</year><volume>226</volume><fpage>59</fpage><lpage>69</lpage><!--PubMed citation query: 'Biochem Biophys Res Comm||226|59||bib33|'--></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuerbitz</surname><given-names>SJ</given-names></name><name><surname>Plunkett</surname><given-names>BS</given-names></name><name><surname>Walsh</surname><given-names>WV</given-names></name><name><surname>Kastan</surname><given-names>MB</given-names></name></person-group><article-title>Wild-type p53 is a cell cycle checkpoint determinant following irradiation</article-title><source>Proc Natl Acad Sci USA</source><year>1992</year><volume>89</volume><fpage>7491</fpage><lpage>7495</lpage><!--PubMed citation query: 'Proc Natl Acad Sci USA||89|7491||bib34|'--></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lemoine</surname><given-names>NR</given-names></name><name><surname>Staddon</surname><given-names>S</given-names></name><name><surname>Dickson</surname><given-names>C</given-names></name><name><surname>Barnes</surname><given-names>DM</given-names></name><name><surname>Gullick</surname><given-names>WJ</given-names></name></person-group><article-title>Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer</article-title><source>Oncogene</source><year>1990</year><volume>5</volume><fpage>237</fpage><lpage>239</lpage><!--PubMed citation query: 'Oncogene||5|237||bib35|'--><pub-id pub-id-type="pmid">2181382</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Rosen</surname><given-names>JM</given-names></name><name><surname>McMenamin-Balano</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>WJ</given-names></name><name><surname>Perkins</surname><given-names>AS</given-names></name></person-group><article-title>neu/ERBB2 cooperates with p53-172H during mammary tumourigenesis in transgenic mice</article-title><source>Mol Cell Biol</source><year>1997</year><volume>17</volume><fpage>3155</fpage><lpage>3163</lpage><!--PubMed citation query: 'Mol Cell Biol||17|3155||bib36|'--><pub-id pub-id-type="pmid">9154814</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Thor</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Barcos</surname><given-names>M</given-names></name><name><surname>Ljung</surname><given-names>B</given-names></name><name><surname>Benz</surname><given-names>C</given-names></name></person-group><article-title>The HER2 (c-<italic>erb</italic>B-2) oncogene is frequently amplified in <italic>in situ</italic> carcinomas of the breast</article-title><source>Oncogene</source><year>1992</year><volume>7</volume><fpage>1027</fpage><lpage>1032</lpage><!--PubMed citation query: 'Oncogene||7|1027||bib37|'--><pub-id pub-id-type="pmid">1349163</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>CJ</given-names></name></person-group><article-title>Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation</article-title><source>Cell</source><year>1995</year><volume>80</volume><fpage>179</fpage><lpage>185</lpage><!--PubMed citation query: 'Cell||80|179||bib38|'--><pub-id pub-id-type="pmid">7834738</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marte</surname><given-names>BM</given-names></name><name><surname>Graus-Porta</surname><given-names>D</given-names></name><name><surname>Jeschke</surname><given-names>M</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Hynes</surname><given-names>NE</given-names></name><name><surname>Taverna</surname><given-names>D</given-names></name></person-group><article-title>NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells</article-title><source>Oncogene</source><year>1995</year><volume>10</volume><fpage>167</fpage><lpage>175</lpage><!--PubMed citation query: 'Oncogene||10|167||bib39|'--><pub-id pub-id-type="pmid">7824269</pub-id></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RR</given-names></name><name><surname>Graves</surname><given-names>JM</given-names></name><name><surname>Warso</surname><given-names>MA</given-names></name><name><surname>Das Gupta</surname><given-names>TK</given-names></name></person-group><article-title>Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice</article-title><source>Br J Cancer</source><year>1995</year><volume>72</volume><fpage>1160</fpage><lpage>1164</lpage><!--PubMed citation query: 'Br J Cancer||72|1160||bib40|'--><pub-id pub-id-type="pmid">7577462</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>DK</given-names></name><name><surname>Kaplan</surname><given-names>DR</given-names></name><name><surname>Escobedo</surname><given-names>JA</given-names></name><name><surname>Rapp</surname><given-names>UR</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name></person-group><article-title>Direct activation of the serine/threonine kinase activity of <italic>raf</italic>-1 through tyrosine phosphorylation by the PDGF receptor</article-title><source>Cell</source><year>1989</year><volume>58</volume><fpage>649</fpage><lpage>657</lpage><!--PubMed citation query: 'Cell||58|649||bib41|'--><pub-id pub-id-type="pmid">2475255</pub-id></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>RC</given-names></name><name><surname>Berg</surname><given-names>P</given-names></name></person-group><article-title>Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase</article-title><source>Proc Natl Acad Sci USA</source><year>1981</year><volume>78</volume><fpage>2072</fpage><lpage>2076</lpage><!--PubMed citation query: 'Proc Natl Acad Sci USA||78|2072||bib42|'--></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nikiforov</surname><given-names>MA</given-names></name><name><surname>Hagen</surname><given-names>K</given-names></name><name><surname>Ossovskaya</surname><given-names>VS</given-names></name><name><surname>Connor</surname><given-names>TM</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Deichman</surname><given-names>GI</given-names></name><name><surname>Gudkov</surname><given-names>AV</given-names></name></person-group><article-title>p53 modulation of anchorage independent growth and experimental metastasis</article-title><source>Oncogene</source><year>1996</year><volume>13</volume><fpage>1709</fpage><lpage>1719</lpage><!--PubMed citation query: 'Oncogene||13|1709||bib43|'--><pub-id pub-id-type="pmid">8895517</pub-id></citation></ref><ref id="bib44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>GC</given-names></name><name><surname>Chantry</surname><given-names>A</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name></person-group><article-title>Adjacent carboxyterminal tyrosine phosphorylation events identify functionally distinct ErbB2 receptor subsets: implications for molecular diagnostics</article-title><source>Exp Cell Res</source><year>1998</year><volume>241</volume><fpage>467</fpage><lpage>475</lpage><!--PubMed citation query: 'Exp Cell Res||241|467||bib44|'--><pub-id pub-id-type="pmid">9637788</pub-id></citation></ref><ref id="bib45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>X</given-names></name><name><surname>Gulliford</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name></person-group><article-title>Transforming growth factor-alpha short-circuits downregulation of the epidermal growth factor receptor</article-title><source>J Cell Physiol</source><year>1999a</year><volume>179</volume><fpage>52</fpage><lpage>57</lpage><!--PubMed citation query: 'J Cell Physiol||179|52||bib45|'--><pub-id pub-id-type="pmid">10082132</pub-id></citation></ref><ref id="bib46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>X</given-names></name><name><surname>Gulliford</surname><given-names>T</given-names></name><name><surname>Doherty</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>GC</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name></person-group><article-title>Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state-specific antibodies</article-title><source>Lancet</source><year>1999b</year><volume>353</volume><fpage>1591</fpage><lpage>1592</lpage><!--PubMed citation query: 'Lancet||353|1591||bib46|'--><pub-id pub-id-type="pmid">10334266</pub-id></citation></ref><ref id="bib47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>X</given-names></name><name><surname>Gulliford</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>GC</given-names></name><name><surname>Epstein</surname><given-names>RJ</given-names></name></person-group><article-title>Association of ErbB2 Ser-1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer</article-title><source>Mol Cell Biochem</source><year>2001</year><volume>218</volume><fpage>47</fpage><lpage>54</lpage><!--PubMed citation query: 'Mol Cell Biochem||218|47||bib47|'--><pub-id pub-id-type="pmid">11330837</pub-id></citation></ref><ref id="bib48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Packham</surname><given-names>G</given-names></name><name><surname>Porter</surname><given-names>CW</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name></person-group><article-title>c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways</article-title><source>Oncogene</source><year>1996</year><volume>13</volume><fpage>461</fpage><lpage>469</lpage><!--PubMed citation query: 'Oncogene||13|461||bib48|'--><pub-id pub-id-type="pmid">8760287</pub-id></citation></ref><ref id="bib49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>AE</given-names></name><name><surname>Andre</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>T</given-names></name><name><surname>Nobrega</surname><given-names>S</given-names></name><name><surname>Soares</surname><given-names>J</given-names></name></person-group><article-title>c-ErbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER&#x0002b;) breast cancer patients with poor prognosis</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>525</fpage><lpage>533</lpage><!--PubMed citation query: 'Ann Oncol||12|525||bib49|'--><pub-id pub-id-type="pmid">11398888</pub-id></citation></ref><ref id="bib50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polet</surname><given-names>H</given-names></name></person-group><article-title>Epidermal growth factor stimulates DNA synthesis while inhibiting cell multiplication of A431 carcinoma cells</article-title><source>Exp Cell Res</source><year>1990</year><volume>186</volume><fpage>390</fpage><lpage>393</lpage><!--PubMed citation query: 'Exp Cell Res||186|390||bib50|'--><pub-id pub-id-type="pmid">2298249</pub-id></citation></ref><ref id="bib51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prevo</surname><given-names>LJ</given-names></name><name><surname>Sanchez</surname><given-names>CA</given-names></name><name><surname>Galipeau</surname><given-names>PC</given-names></name><name><surname>Reid</surname><given-names>BJ</given-names></name></person-group><article-title>p53-mutant clones and field defects in Barrett's esophagus</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>4784</fpage><lpage>4787</lpage><!--PubMed citation query: 'Cancer Res||59|4784||bib51|'--><pub-id pub-id-type="pmid">10519384</pub-id></citation></ref><ref id="bib52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pumiglia</surname><given-names>KM</given-names></name><name><surname>Decker</surname><given-names>SJ</given-names></name></person-group><article-title>Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>448</fpage><lpage>452</lpage><!--PubMed citation query: 'Proc Natl Acad Sci USA||94|448||bib52|'--></citation></ref><ref id="bib53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sainsbury</surname><given-names>JRC</given-names></name><name><surname>Sherbet</surname><given-names>GV</given-names></name><name><surname>Farndon</surname><given-names>JR</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title>Epidermal growth factor receptors and oestrogen receptors in human breast cancer</article-title><source>Lancet</source><year>1985</year><volume>i</volume><fpage>364</fpage><lpage>366</lpage><!--PubMed citation query: 'Lancet||i|364||bib53|'--></citation></ref><ref id="bib54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Godolphin</surname><given-names>W</given-names></name><name><surname>Jones</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Studies of the HER-2/<italic>neu</italic> proto-oncogene in human breast and ovarian cancer</article-title><source>Science</source><year>1989</year><volume>244</volume><fpage>707</fpage><lpage>712</lpage><!--PubMed citation query: 'Science||244|707||bib54|'--><pub-id pub-id-type="pmid">2470152</pub-id></citation></ref><ref id="bib55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slichenmeyer</surname><given-names>WJ</given-names></name><name><surname>Nelson</surname><given-names>WG</given-names></name><name><surname>Slebos</surname><given-names>RJ</given-names></name><name><surname>Kastan</surname><given-names>MB</given-names></name></person-group><article-title>Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>4164</fpage><lpage>4168</lpage><!--PubMed citation query: 'Cancer Res||53|4164||bib55|'--><pub-id pub-id-type="pmid">8364909</pub-id></citation></ref><ref id="bib56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorkin</surname><given-names>A</given-names></name><name><surname>Di Fiore</surname><given-names>PP</given-names></name><name><surname>Carpenter</surname><given-names>G</given-names></name></person-group><article-title>The carboxyl terminus of epidermal growth factor receptor/<italic>erb</italic>B-2 chimerae is internalization impaired</article-title><source>Oncogene</source><year>1993</year><volume>8</volume><fpage>3021</fpage><lpage>3028</lpage><!--PubMed citation query: 'Oncogene||8|3021||bib56|'--><pub-id pub-id-type="pmid">8105439</pub-id></citation></ref><ref id="bib57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tagliabue</surname><given-names>E</given-names></name><name><surname>Centis</surname><given-names>F</given-names></name><name><surname>Campiglio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Selection of monoclonal antibodies which induce internalization and phosphorylation of p185<sup>HER2</sup> and growth inhibition of cells with HER2/<italic>neu</italic> gene amplification</article-title><source>Int J Cancer</source><year>1991</year><volume>47</volume><fpage>933</fpage><lpage>937</lpage><!--PubMed citation query: 'Int J Cancer||47|933||bib57|'--><pub-id pub-id-type="pmid">1672668</pub-id></citation></ref><ref id="bib58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Towbin</surname><given-names>H</given-names></name><name><surname>Staehelin</surname><given-names>T</given-names></name><name><surname>Gordon</surname><given-names>J</given-names></name></person-group><article-title>Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications</article-title><source>Proc Natl Acad Sci USA</source><year>1979</year><volume>76</volume><fpage>4350</fpage><lpage>4354</lpage><!--PubMed citation query: 'Proc Natl Acad Sci USA||76|4350||bib58|'--></citation></ref><ref id="bib59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Traverse</surname><given-names>S</given-names></name><name><surname>Gomez</surname><given-names>N</given-names></name><name><surname>Paterson</surname><given-names>H</given-names></name><name><surname>Marshall</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><article-title>Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells</article-title><source>Biochem J</source><year>1992</year><volume>288</volume><fpage>351</fpage><lpage>355</lpage><!--PubMed citation query: 'Biochem J||288|351||bib59|'--><pub-id pub-id-type="pmid">1334404</pub-id></citation></ref><ref id="bib60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>H</given-names></name><name><surname>Sakamaki</surname><given-names>C</given-names></name><name><surname>Tsugane</surname><given-names>S</given-names></name><name><surname>Fukutomi</surname><given-names>T</given-names></name><name><surname>Hirohashi</surname><given-names>S</given-names></name></person-group><article-title>A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases</article-title><source>Breast Cancer Res Treat</source><year>1998</year><volume>48</volume><fpage>21</fpage><lpage>32</lpage><!--PubMed citation query: 'Breast Cancer Res Treat||48|21||bib60|'--><pub-id pub-id-type="pmid">9541186</pub-id></citation></ref><ref id="bib61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tyner</surname><given-names>SD</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Laucirica</surname><given-names>R</given-names></name><name><surname>Ford</surname><given-names>RJ</given-names></name><name><surname>Donehower</surname><given-names>LA</given-names></name></person-group><article-title>Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53</article-title><source>Mol Carcinogenesis</source><year>1999</year><volume>24</volume><fpage>197</fpage><lpage>208</lpage><!--PubMed citation query: 'Mol Carcinogenesis||24|197||bib61|'--></citation></ref><ref id="bib62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Slooten</surname><given-names>HJ</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>Borresen</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma</article-title><source>J Pathol</source><year>1999</year><volume>189</volume><fpage>504</fpage><lpage>513</lpage><!--PubMed citation query: 'J Pathol||189|504||bib62|'--><pub-id pub-id-type="pmid">10629550</pub-id></citation></ref><ref id="bib63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasey</surname><given-names>PA</given-names></name><name><surname>Jones</surname><given-names>NA</given-names></name><name><surname>Jenkins</surname><given-names>S</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name></person-group><article-title>Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance</article-title><source>Mol Pharmacol</source><year>1996</year><volume>50</volume><fpage>1536</fpage><lpage>1540</lpage><!--PubMed citation query: 'Mol Pharmacol||50|1536||bib63|'--><pub-id pub-id-type="pmid">8967975</pub-id></citation></ref><ref id="bib64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>D</given-names></name><name><surname>Parry</surname><given-names>D</given-names></name><name><surname>Cherwinski</surname><given-names>H</given-names></name><name><surname>Bosch</surname><given-names>E</given-names></name><name><surname>Lees</surname><given-names>E</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name></person-group><article-title>Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21<sup>Cip1</sup></article-title><source>Mol Cell Biol</source><year>1997</year><volume>17</volume><fpage>5598</fpage><lpage>5611</lpage><!--PubMed citation query: 'Mol Cell Biol||17|5598||bib64|'--><pub-id pub-id-type="pmid">9271435</pub-id></citation></ref><ref id="bib65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>M</given-names></name><name><surname>Grim</surname><given-names>J</given-names></name><name><surname>Deshane</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Strong</surname><given-names>TV</given-names></name><name><surname>Siegal</surname><given-names>GP</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name></person-group><article-title>An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2</article-title><source>Gene Ther</source><year>1997</year><volume>4</volume><fpage>317</fpage><lpage>322</lpage><!--PubMed citation query: 'Gene Ther||4|317||bib65|'--><pub-id pub-id-type="pmid">9176517</pub-id></citation></ref><ref id="bib66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyllie</surname><given-names>FS</given-names></name><name><surname>Haughton</surname><given-names>MF</given-names></name><name><surname>Blaydes</surname><given-names>JP</given-names></name><name><surname>Schlumberger</surname><given-names>M</given-names></name><name><surname>Wynford-Thomas</surname><given-names>D</given-names></name></person-group><article-title>Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells</article-title><source>Oncogene</source><year>1995</year><volume>10</volume><fpage>49</fpage><lpage>59</lpage><!--PubMed citation query: 'Oncogene||10|49||bib66|'--><pub-id pub-id-type="pmid">7529918</pub-id></citation></ref><ref id="bib67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Tainsky</surname><given-names>MA</given-names></name><name><surname>Bischoff</surname><given-names>FZ</given-names></name><name><surname>Strong</surname><given-names>LC</given-names></name><name><surname>Wahl</surname><given-names>GM</given-names></name></person-group><article-title>Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles</article-title><source>Cell</source><year>1992</year><volume>70</volume><fpage>937</fpage><lpage>948</lpage><!--PubMed citation query: 'Cell||70|937||bib67|'--><pub-id pub-id-type="pmid">1525830</pub-id></citation></ref><ref id="bib68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>XY</given-names></name><name><surname>Hu</surname><given-names>GY</given-names></name><name><surname>Liu</surname><given-names>WB</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Deisseroth</surname><given-names>AB</given-names></name></person-group><article-title>A temperature-sensitive mutant of human p53</article-title><source>EMBO J</source><year>1994</year><volume>13</volume><fpage>2535</fpage><lpage>2544</lpage><!--PubMed citation query: 'EMBO J||13|2535||bib68|'--><pub-id pub-id-type="pmid">8013454</pub-id></citation></ref></ref-list></back></article>


